drugset / Trial / NCT06289647
Azithromycin Reduction to Reach Elimination of Trachoma B
Phase 4
Withdrawn
University of California, San Francisco
Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo · collabNational Eye Institute (NEI) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The investigators propose a randomized controlled trial of discontinuation versus continuation of annual mass azithromycin distribution in hypoendemic communities of Maniema, DRC. The investigators will randomize communities with up to 20% Trachomatous Inflammation - Follicular (TF) prevalence following at least 5 years of mass azithromycin distribution to discontinuation or continuation of 3 additional years of annual mass azithromycin distribution.
Timeline
- Start
- 2024-10
- Primary completion
- 2029-08-31
- Completion
- 2029-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azithromycin | Small molecule | 20 mg/kg | Oral |
| Comparator | Azithromycin | Small molecule | 1 g | Oral |